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Objective. We compared the use of secondary prevention among patients with a first-time hospitalisation for peripheral
arterial disease (PAD) of the lower limb with that among patients with a first-time hospitalisation for myocardial infarction
(MI).
Design and materials. Population-based follow-up study between 1997 and 2003 using registry data from the counties of
Northern Jutland, Aarhus and Viborg, Denmark.
Results. Between 1997 and 2003, within 180 days after hospital discharge, 26% of patients with lower limb PAD
(n¼ 3,424) used antiplatelet drugs, 10% statins, 22% ACE-inhibitors/AT-II receptor antagonists and 13% betablockers
compared with 55%, 46%, 42% and 78% respectively among patients with MI (n¼ 11,927). Patients with PAD were sub-
stantially less likely than patients with MI to use antiplatelet drugs [adjusted relative risk (RR)¼ 0.39 (95% confidence
interval (CI): 0.36e0.41)], statins [adjusted RR¼ 0.21 (95% CI: 0.19e0.23)], ACE-inhibitors/AT-II receptor antagonists
[adjusted RR¼ 0.43 (95% CI: 0.40e0.47)] and beta-blockers [adjusted RR¼ 0.10 (95% CI: 0.09e0.11). Between 1997
and 2003 secondary prevention increased considerably in both patient groups, but the disparity in treatment persisted.
Conclusions. Efforts to further increase secondary prevention among patients with PAD are needed urgently.
 2007 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.
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Patients with peripheral arterial disease (PAD) are at
high risk of myocardial infarction (MI), stroke and
death from vascular causes.1 Since the mid-1990s,
they have been considered similar to patients with
coronary heart disease (CHD) in terms of need for in-
tensive risk factor modification and secondary pre-
vention, supported by evidence from randomized
controlled clinical trials and meta-analyses which is
included in current national and international guide-
lines.2e6
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ing antiplatelet drugs, statins, angiotensin converting
enzyme (ACE)-inhibitors and beta-adrenoceptor
blocking agents (beta-blockers) was infrequent in pa-
tients with PAD, according to available reports, based
primarily on selected populations.2,7e16 Population-
based comparisons of secondary prevention among
patients with PAD and those with other forms of
ischemic cardiovascular disease remain sparse.
We therefore conducted a hospital-based follow-up
study to examine the frequency of secondary preven-
tion among patients with lower limb PAD compared
with MI patients between 1997 and 2003.
Material and Methods
This population-based follow-up was conducted
from January 1, 1997 to December 31, 2003 in Northn behalf of European Society for Vascular Surgery.
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(population¼ 1.4 million, approximately 25% of the
total Danish population). The Danish National
Health Service provides tax-supported health care
for all inhabitants, with free access to general practi-
tioners, hospitals, public clinics and reimbursement
of a variable proportion of the cost of prescribed
drugs.17 Each Danish citizen receives a unique civil
registration number at birth, which encodes gender
and date of birth and allows accurate linkage to mul-
tiple population-based registries. The civil registra-
tion number permits compilation of a complete
hospital discharge and prescription history for each
individual under study.18
Identification of patients
Hospital discharge registries contain key information
on all patients discharged from non-psychiatric hospi-
tals in the counties since 1972 (Viborg) and 1977
(Northern Jutland and Aarhus), respectively.19 These
registries include patients’ civil registration numbers,
hospital discharge dates, and up to 20 discharge diag-
noses, assigned by physicians according to the Inter-
national Classification of Diseases, 8th revision until
the end of 1993, and 10th revision thereafter.19
We identified all patients with a first-time dis-
charge diagnosis of PAD (ICD-8 code: 440.20; ICD-10
code: I70.2) or MI (ICD-8 code 410; ICD-10 code: I21)
during the study period. To be eligible for the study,
patients could not have a previous diagnosis of either
PAD or MI in the hospital discharge registries during
the 1972/1977e1996 period. We also excluded pa-
tients who did not survive hospital admission
(n¼ 1,792), and those with an address outside the
counties (n¼ 5). In total, 3,424 patients with PAD
and 11,927 patients with MI were included in the
analyses.
Patients with PAD were diagnosed most often by
vascular surgeons (72%), while MI patients were diag-
nosed mainly by cardiologists or internists (75%).
Among patients with PAD, we identified hospitalisa-
tions for MI within 180 days after hospital discharge
for PAD. Because routinely coded discharge diagnoses
are not always entirely accurate, we also identified
a subpopulation of PAD for which the diagnoses pre-
sumably had a very high positive predictive value
(i.e., patients with a PAD diagnosis who had an addi-
tional procedure or surgical code related to PAD
(ICD-10: KPEH, KPFH, KPEU, KPFU, KPEF, KPEN,
KPEP, KPFP, KPEQ, KPFQ, KPET, KPFT, KPEE,
KPFE) within 180 days following their first PAD
admission.Eur J Vasc Endovasc Surg Vol 35, January 2008Data on secondary prevention
We obtained data on use of cardiovascular drugs by
study patients from population-based prescription
databases.20 These databases contain key information
on prescriptions for reimbursable drugs dispensed
from all pharmacies in the three counties during the
study period. Information includes patients’ civil reg-
istration numbers, type of drug prescribed according
to the anatomic therapeutic chemical (ATC) classifica-
tion system,21 and date dispensed. We identified all
prescriptions for antiplatelet drugs [including low-
dose acetylsalicylic acid (aspirin), dipyridamole and
clopidogrel], statins, ACE-inhibitors, angiotensin-II
(AT-II) receptor antagonists, and selective and non-
selective beta-blockers filled within 180 days after
hospital discharge. All the drugs noted above are
available only by prescription, except for low-dose
aspirin. However, aspirin is available by prescription
to patients with chronic diseases and to pensioners,
and they are reimbursed for it. In such cases, use is re-
corded in the prescription databases. We also col-
lected information on use of combination therapy
with an antiplatelet drug, a statin, and a beta-blocker,
an ACE-inhibitor, or an AT-II receptor antagonist.
We defined use as filling at least one prescription
within 180 days following discharge with a PAD or
MI diagnosis.
Data on covariates
Data were obtained from the discharge and prescrip-
tion databases based on the available history for each
patient with PAD or MI.
To adjust for coexisting morbidity, which might
affect the likelihood of being prescribed secondary
preventive drugs, we calculated comorbidity index
scores using the technique developed by Charlson
et al. The Charlson Comorbidity Index has been vali-
dated for the prediction of short- and long-term mor-
tality for patients with a wide range of conditions.22 It
covers 19 major disease categories, including diabetes
mellitus, congestive heart failure, cerebrovascular dis-
ease and cancer, weighted according to their prognos-
tic impact on patient survival. The Index previously
was adapted and validated for use with hospital dis-
charge registry data.23 We defined three levels of co-
morbidity for each patient: 0 comorbidities (‘‘none’’)
for patients with no recorded underlying diseases
included in the Charlson Index; a score of 1e2 (‘‘low
comorbidity’’); and a score >2 (‘‘high comorbidity’’).
These three levels were included as design variables
in our analyses. Diagnoses of PAD and MI were
excluded from the index.
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Eur J Vasc Endovasc Surg Vol 35, January 2008In order to increase the likelihood of capturing
diabetic status, we defined diabetes mellitus as a dis-
charge diagnosis of diabetes mellitus registered be-
fore the admission for PAD or MI, and/or at least
one filled prescription for insulin or an oral antidia-
betic drug prior to the admission for PAD or MI.
We defined hypertension as a discharge diagnosis
of hypertension prior to the admission for PAD or
MI, and/or at least one filled prescription for an anti-
hypertensive agent.
Statistical analysis
The proportions of individual drug classes used
among patients with PAD, with PAD and surgery or
MI were calculated by calendar year.
Cox proportional hazard regression analysis was
used to compute the hazard ratio as a measure of
the relative risk (RR) with 95% confidence intervals
(95% CI) for patients with PAD filling a prescription
for a cardiovascular drug within 180 days following
discharge, compared with patients with MI. Length
of follow-up was defined as the time from discharge
until the date a prescription was filled for a specific
drug, death, emigration or end of follow-up, which-
ever came first. We repeated the analyses for patients
with PAD who underwent surgery compared with
patients with MI.
Analyses were stratified by sex, age, calendar time,
Charlson Index, type of department (vascular surgery,
cardiology, other) and hospital (university, non-
teaching). Finally, we assessed drug use within 180
days before hospital admission among both PAD
and MI patients. All analyses were performed using
SAS statistical package version 9.13 (SAS Institute
Inc., Cary, NC, USA).
Results
Characteristics of the patients with lower limb PAD
(all patients and patients undergoing surgery sepa-
rately) and those with MI are shown in Table 1. Pa-
tients with PAD were older than patients with MI.
Nearly half of PAD patients were women, compared
with 36% of MI patients. Diabetes and hypertension
were more prevalent among patients with PAD com-
pared with those with MI (23.6% vs. 11.6%, and
71.5% vs. 56.2%, respectively). Patients with lower ex-
tremity PAD undergoing surgery (n¼ 1,168) were
slightly younger and had slightly less chronic disease
than all PAD patients combined. Among patients with
PAD, 1.7% had a first-time MI within 180 days after
discharge for PAD.Drug classes used by patients with PAD, patients
with PAD undergoing surgery and MI during the first
180 days after hospital discharge are shown in Table 2.
Patients with PAD were up to 10 times less likely to
receive secondary prevention therapy with any drug
class compared with MI patients and even less likely
to receive combination therapy [adjusted RR¼ 0.04
(95% CI: 0.02e0.05)]. The largest differences between
patients with PAD and those with MI occurred for sta-
tin use [adjusted RR¼ 0.21 (95% CI: 0.19e0.23)] and
beta-blockers [adjusted RR¼ 0.10 (95% CI: 0.09e0.11)].
The results for statins, ACE-inhibitors and beta-
blockers were nearly unchanged when we compared
patients with PAD who underwent surgery with
patients with MI. The difference in antiplatelet drug
use was slightly less pronounced, but still significant
[adjusted RR¼ 0.46 (95% CI: 0.42e0.51) vs. adjusted
RR¼ 0.39 (95% CI: 0.36e0.41) in the full analysis].
The pattern of marked differences in secondary
prevention was found consistently in subgroup analy-
ses (Fig. 1). The difference in aspirin use was more
pronounced in more recent years due to greatly in-
creased uptake among patients with MI. There was
a trend toward lower treatment differences for all
drug classes among patients with a higher Charlson
Index level, i.e., with increasing comorbidity. Similar
differences were found consistently when stratifying
for type of department and hospital (data not shown).
We also assessed prescription patterns stratified by
type of department as a proxy to assess potential
differences in treatment behaviour between vascular
surgeons, cardiologists and other specialists. Between







Total 3,424 (100) 1,168 (100) 11,927 (100)
Men 1,731 (50.6) 631 (54.0) 7,636 (64.0)







<65 1,006 (29.4) 326 (28) 4,600 (38.6)
65e74 985 (28.8) 402 (34) 3,179 (26.7)
75þ 1,433 (41.9) 440 (38) 4,148 (34.8)
Comorbidity
Diabetes 809 (23.6) 281 (24.1) 1,384 (11.6)
Hypertension 2,448 (71.5) 835 (71.5) 6,707 (56.2)
Congestive heart
failure
394 (11.5) 113 (9.7) 695 (5.8)
Cerebrovascular
disease
581 (16.9) 176 (15.1) 1,178 (9.8)
Charlson Comorbidity Index
Low 1,494 (43.6) 529 (45.3) 7,640 (64.1)
Medium 1,345 (39.3) 464 (39.7) 3,411 (28.6)
High 585 (17.1) 175 (15.0) 876 (7.3)
54 C. Gasse et al.Table 2. Proportion of patients with lower limb PAD or MI, who filled at least one prescription for specific drug classes or for
combinationx therapy within 180 days after discharge during the study period (1997e2003), and adjusted relative risks with 95%
confidence intervals (CI)
Lower limb PAD
(N¼ 3,424) N (%)
Lower limb PAD
with surgery








Antiplatelet drugs 883 (25.7) 365 (31.3) 6,605 (55.3) 0.39 (0.36e0.41) 0.46 (0.42e0.51)
Statins 349 (10.1) 140 (12.0) 5,463 (45.8) 0.21 (0.19e0.23) 0.23 (0.20e0.28)
ACE-inhibitors/AT-II receptor
antagonists
737 (21.5) 290 (24.8) 5,003 (41.9) 0.43 (0.40e0.47) 0.50 (0.44e0.56)
Beta-blockers 447 (13.0) 175 (15.0) 9,246 (77.5) 0.10 (0.09e0.11) 0.11 (0.09e0.13)
Combination therapyx 97 (2.8) 50 (4.3) 3,700 (31.0) 0.04 (0.02e0.05) 0.14 (0.11e0.19)
* PAD patients versus MI patients.
z PAD patients with surgery versus MI patients.
y Relative Risk (RR) adjusted for age, gender, calendar year, and Charlson Comorbidity Index.
x Combination therapy consisted of an antiplatelet drugþ beta-blocker or ACE inhibitor or AT-II receptor antagonistþ statin.1997 and 2003, patients with PAD discharged from
vascular departments filled prescriptions for antipla-
telet drugs and ACE inhibitors within 180 days after
discharge as often as did patients with PAD dis-
charged from cardiology departments (27.5% vs.
29.5%, 22.2% vs. 22.7%, respectively). Patients with
PAD discharged from vascular departments filled
prescriptions for statins more frequently (12.2%) and
prescriptions for betablockers less often (13.6%) than
patients with PAD discharged from cardiology de-
partments (8.5% and 17.6%, respectively). The lowest
prevalence of filled prescriptions for all drug classes
was found among patients with PAD discharged
from other departments (Antiplatelet drugs: 19.2%;
Statins; 4.2%; ACE-inhibitors/AT-II receptor anata-
gonists: 19.0%; betablockers: 10.3%, and combination
therapy: 0.8%).
A minority of both PAD (7.3%e18.8%) and MI pa-
tients (6.0%e16.7%) already were using the studied
cardiovascular drugs at the time of admission. The
increase in drug use following admission was sub-
stantially smaller among PAD patients when com-
pared with their MI counterparts.
Cardiovascular drug use for secondary prevention
between 1997 and 2003
Figs. 2 and 3 show the changing patterns in cardiovas-
cular drug use for secondary prevention over the 7-
year study period. In 1997, antiplatelet drugs (23%)
were the most frequently used drug class among pa-
tients with PAD, followed by ACE inhibitors/AT-II re-
ceptor antagonists (14%), beta-blockers (9%) and
statins (3%). Among patients with MI, beta-blockers
were the most frequently prescribed drugs (74%), fol-
lowed by antiplatelet drugs (38%), ACE-inhibitors/
AT-II receptor antagonists (35%) and statins (17%).Eur J Vasc Endovasc Surg Vol 35, January 2008Over the 7-year period, thereweremarked increases
in the use of almost all these drug classes in patients
with PAD or MI. In patients with PAD, the increase
in antiplatelet and statin use was most pronounced
between 2000 and 2003, while ACE inhibitor use and
betablocker use increasedmore steadily over thewhole
study period, with a reduction in betablocker use
by 4.6% between 2002 and 2003. Thus, antiplatelet
drugs (41%) remained the most frequently used drug
class in patients with PAD in 2003, followed by ACE-
inhibitor/AT-II receptor antagonists (28%), and statins
(22%). Beta-blocker use remained particularly low
at 15%. Among patients with MI, all drug classes in-
creased steadily over the study period except for beta-
blockers (76.2% in 2003), which were surpassed
by antiplatelet drugs (83%) in 2003. Statins were used
by 70.5% and ACE inhibitors/AT-II receptor antago-
nists by 52.7%. The increases for antiplatelet drugs, sta-
tins, and ACE inhibitors/AT-II receptor antagonists
were most pronounced between 2001 and 2002 and
thereafter. Combination therapy increased steadily
from 0.8% in 1997 to 9.6% in 2003 among patients
with PAD, and from 6.4% in 1997 to 62.1% in 2003
among patients with MI. Throughout the study
period, patients with PAD were less frequently treated
with drugs for secondary prevention than patients
with MI.
Discussion
Use of secondary prevention increased markedly
between 1997 and 2003 among Danish patients with
PAD and MI. However, as of 2003 the proportion of
treated patients with PAD who received treatment
for secondary prevention remained below 40% for
all drug classes, compared to 50%e85% for patients
with MI. This finding held in all subgroup analyses.
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Antiplatelet drugs
Overall (adjusted) 0.39 (0.36, 0.42)
Age <65 y 0.31 (0.27, 0.35)
>= 65 0.44 (0.40, 0.47)
Gender Men 0.38 (0.34, 0.42)
Women 0.40 (0.36, 0.44)
Calendar year 1997−2000 0.48 (0.43, 0.53)
2001−2003 0.32 (0.29, 0.36)
Charlson index Low 0.33 (0.30, 0.37)
Medium 0.45 (0.40, 0.50)
High 0.43 (0.35, 0.52)
Statins
Overall (adjusted) 0.20 (0.19, 0.23)
Age <65 y 0.20 (0.17, 0.23)
>= 65 0.21 (0.18, 0.24)
Gender Men 0.21 (0.18, 0.24)
Women 0.21 (0.17, 0.24)
Calendar year 1997−2000 0.20 (0.17, 0.24)
2001−2003 0.21 (0.19, 0.24)
Charlson index Low 0.18 (0.15, 0.21)
Medium 0.22 (0.18, 0.26)
High 0.34 (0.25, 0.46)
ACE−inhibitor/AT− II receptor antagonists
Overall (adjusted) 0.43 (0.40, 0.46)
Age <65 y 0.39 (0.34, 0.46)
>= 65 0.44 (0.40, 0.48)
Gender Men 0.44 (0.39, 0.49)
Women 0.42 (0.38, 0.47)
Calendar year 1997−2000 0.46 (0.41, 0.51)
2001−2003 0.44 (0.39, 0.49)
Charlson index Low 0.30 (0.26, 0.35)
Medium 0.43 (0.38, 0.49)
High 0.63 (0.53, 0.75)
Beta−blockers
Overall (adjusted) 0.10 (0.09, 0.11)
Age <65 y 0.07 (0.05, 0.08)
>= 65 0.12 (0.11, 0.13)
Gender Men 0.08 (0.08, 0.10)
Women 0.11 (0.09, 0.12)
Calendar year 1997−2000 0.08 (0.07, 0.09)
2001−2003 0.12 (0.11, 0.14)
Charlson index Low 0.06 (0.06, 0.08)
Medium 0.13 (0.12, 0.16)











Fig. 1. Adjusted relative risk and 95% confidence intervals (CI) for patients with lower limb PAD who filled a prescription
for a cardiovascular drug within 180 days after hospital discharge, compared with patients with MI, stratified by sex, age,
calendar time and Charlson Index. [Adjusted for sex, age, calendar time and Charlson Index unless stratified for one of
these variables].Comparisons with other studies
The under-treatment of patients with PAD seen
in our study accords with other studies conducted
in the U.S. and Europe, although the proportion ofpatients treated appears particularly low in
Denmark.2,7e16 Indications of low treatment rates
among Danish patients with PAD have
been reported previously for selected smaller study
populations.14,15Eur J Vasc Endovasc Surg Vol 35, January 2008
56 C. Gasse et al.In contrast, the use of statins and aspirin in primary
care was already about 50% in the US in 1999.7 Even
higher proportions were found in a study conducted
in a US university clinic between 2002 and 2003
among elderly patients with PAD: 85% were taking
antiplatelet drugs, 67% lipid-lowering drugs, 60%
beta-blockers, and 62% ACE-inhibitors/AT-II receptor
antagonists.13 A German study found that 75% of pa-
tients with PAD were treated with antiplatelet drugs
in 2001.10 Lower proportions have been reported
from the UK; there only 25% of patients with PAD
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Fig. 2. Proportion (%) of treated patients with lower limb
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Fig. 3. Proportion (%) of treated patients with MI by drug
class and calendar year.Eur J Vasc Endovasc Surg Vol 35, January 2008beta-blockers in 1996.11 The marked disparities we
found in the treatment of patients with PAD vs. MI
in our study accord with US studies, which detected
differences of 12%e45% for treatment with aspirin
and statins between the two patient populations.7,12,13
Differences in treatment of PAD and MI patients
may have several explanations. First, guidelines on
secondary prevention therapy after MI had been pub-
lished and partly implemented in clinical practice in
Denmark at the start of the study period.4,5,24
Specific national guidelines for treatment of PAD
were not published until 2005 and Danish clinicians
therefore had to rely on international guidelines
when considering secondary prevention during the
study period.5 At the start of the study period only
anti-platelet therapy was recommended for all pa-
tients with PAD in international guidelines.25,26 The
first Trans-Atlantic Inter-Socitety Concensus (TASC)
on PAD was published in 2000 recommending the
use of aspirin and statins in all patients with PAD
even though clinical evidence for statin use in patients
with PAD was still lagging behind the clinical evi-
dence for statin use in patients with MI.27 In 2000
the HOPE study indicated beneficial cardioprotective
effects of ACE-inhibitors in patients beyond blood
pressure lowering effects, while it was reemphasized
that beta-blockers were no longer regarded as contra-
indicated in PAD patients, and their use was con-
sidered potentially cardioprotective.28,29
The potential influence of the PAD specific guide-
lines and the increasing evidence for the use of aspi-
rin, statins and ACE-inhibitors in patients with PAD
is reflected by the increasing frequency of filled
prescription for these drugs after the year 2000.
Beta-blocker use, however, remained low.
Other explanations for lower use of antiplatelet
drugs and statins in patients with PAD include differ-
ent prescribing behaviour between the treating speci-
alities. It has been reported that vascular surgeons
were less likely to report ‘almost always’ prescribing
of antiplatelet drugs and had higher thresholds for
initiating lipid-lowering therapy for patients with
PAD than cardiologists.9 However, patients with
PAD discharged from vascular surgery or cardiology
departments in our study filled prescriptions for anti-
platelet therapy within the 180 days after discharge to
the same degree and prescriptions for statins were
even more frequently filled by patients discharged
from vascular surgery departments. In addition,
some regulatory requirements of the Danish National
Health Service may have lowered the frequency of
statin treatment in patients with PAD. While patients
with ischaemic heart disease began to receive auto-
matic reimbursement for the costs of statins in
57Secondary Prevention in Patients with PAD or MIJanuary 1999, patients with PAD were required to file
individual applications to receive reimbursement
throughout the study period.
Finally, responsibility for treatment and care of pa-
tients with PAD does not rest with a well-defined,
dedicated speciality in Denmark. It is spread out
across a number of specialities, including family med-
icine, vascular surgery, cardiology and internal medi-
cine.23 Not all physicians caring for patients with PAD
in Denmark have up-to-date evidence-based informa-
tion about PAD, including use of appropriate second-
ary prevention. Our sub-analysis of patients with PAD
discharged from University hospitals versus non-
teaching hospitals revealed no difference in treatment
prevalence, indicating that treatment attitudes among
physicians are generally low for patients with PAD.
Recently, there has been a concerted effort to dissem-
inate information about secondary treatment of PAD
and to improve clinical practice,30e32 and it is notable
that an innovative intervention program within a ded-
icated PAD rehabilitation clinic succeeded in treating
a very high proportion of patients with aspirin
(88%) and statins (92%).33
Strengths and limitations of the study
The main strengths of our study are its prospective,
population-based design, large size and availability
of a unique civil registration number for each patient,
which allowed accurate identification and linkage be-
tween public data sources. We were able to identify
patients with incident diagnoses and to control for
co-morbidity, capitalizing on the 20 years of data con-
tained in the hospital discharge registries.
Limitations include the use of hospital discharge
diagnoses, which may not always be accurate. How-
ever, it has been reported that the predictive value
of an MI discharge diagnosis in Denmark is high,
with misclassification occurring in less than 10% of
cases.34 Although the lower limb PAD discharge diag-
nosis has not yet been validated, the fact that in our
study the diagnosis was made primarily by vascular
surgeons indicates the likelihood of good data quality.
It is reassuring that the results did not significantly
change when we reduced the risk of misclassification
by restricting our analysis to patients hospitalised
with PAD of the lower extremities who underwent
surgery.
Because we focused only on patients hospitalized
with lower extremity PAD, excluding those with
milder and asymptomatic forms, we probably under-
estimated the true incidence of this condition. Under-
treatment of PAD in general practice is likely to beeven more pronounced than among patients diag-
nosed in a hospital.
The presence of cardiovascular risk factors cannot
be completely ascertained from discharge data. How-
ever, we did find that patients with PAD were hospi-
talised more often for hypertension, diabetes, stroke
and congestive heart failure than MI patients. Thus,
the decision to use secondary prevention may depend
on the type of arterial disease manifested initially,
rather than on patient specific risk profiles.
We were not able to examine whether the low pro-
portion of patients with PAD who received secondary
preventive treatment after hospital discharge
stemmed from physicians’ failure to write prescrip-
tions or from patients’ reluctance to fill them. Also it
is possible that we underestimated aspirin use both
among PAD and MI patients, as it is available without
a prescription. Patients may have been advised just
verbally by their physicians to take low-dose aspirin.
We also had limited information about possible
contraindications among study patients. Finally, it
is important to note that we determined whether pa-
tients filled at least one prescription, but we did not
assess adherence to drug treatment or success in
meeting treatment goals.
Conclusion
Patients with PAD were treated less frequently with
drugs used for secondary prevention of cardiovascu-
lar disease than were patients with an incident MI.
However, secondary prevention increased substan-
tially between 1997 and 2003 in both patient groups.
The attention of the medical community and the pub-
lic should be further directed towards patients with
PAD, who are at high risk for cardiovascular events.
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